Literature DB >> 10710269

Spontaneously occurring anti-PTH autoantibodies must be considered in the differential diagnosis of patients with elevated serum PTH levels.

B Cavaco1, V Leite, M M Loureiro, M F Ferreira, M C Pereira, M A Santos, L G Sobrinho.   

Abstract

We investigated the cause of elevated immunoreactive circulating parathyroid hormone (PTH) levels in two females of 41 (case 1) and 39 (case 2) years of age with low/normal serum calcium levels and hypocalcemia, respectively, and, in the latter case, hyperprolactinemia. Serum samples from both patients were fractionated by Sephadex G-100 Superfine chromatography. Fractions were assayed for PTH and prolactin (PRL) by immunoradiometric assays (IRMA) and for immunoglobulin G (IgG) by radial immunodiffusion. Sera from both patients were incubated with protein A and protein G Sepharose, centrifugated and the supernatant was assayed for PTH by IRMA. Sera were also subjected to affinity chromatography with an anti-human-IgG-agarose column. IgG and PTH or PRL were measured in the fractions by radial immunodiffusion and IRMA, respectively. In both cases the majority of serum PTH immunoreactivity eluted in the same fractions of IgG after gel filtration and was precipitated by protein A (89% in patient 1 and 96% in patient 2) and protein G (83% in patient 1 and 100% in patient 2), thus, behaving as IgG. In case 1, 79% of PTH was also retained by an anti-hIgG agarose column. High PRL levels in patient 2 were due to macroprolactinemia since most of PRL eluted as big,big (40%) and big-PRL (45%) after gel filtration. Forty-eight percent of PRL from patient 2 was retained by the anti-hIgG column indicating the presence of an anti-PRL autoantibody. These data suggest that spontaneously occurring anti-PTH autoantibodies must be considered in the differential diagnosis of patients with elevated serum PTH levels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10710269     DOI: 10.1007/BF03343654

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  16 in total

1.  ANTIBODIES TO HUMAN GROWTH HORMONE (HGH) IN HUMAN SUBJECTS TREATED WITH HGH.

Authors:  J ROTH; S M GLICK; R S YALOW; S A BERSON
Journal:  J Clin Invest       Date:  1964-06       Impact factor: 14.808

2.  Spontaneously occurring antibodies to parathyroid hormone.

Authors:  M Wilkinson; A McElduff; J Wilson; P Haber; A Freeman; M Robertson; P Mathews
Journal:  J Clin Endocrinol Metab       Date:  1990-06       Impact factor: 5.958

3.  Antibodies to human growth hormone. Development during therapy with human growth hormone.

Authors:  S D Frasier; F G Smith
Journal:  Am J Dis Child       Date:  1966-11

4.  Autoantibodies against parathyroid hormone in a patient with terminal renal insufficiency.

Authors:  H Jüppner; M J Atkinson; R Baethke; R D Hesch
Journal:  Lancet       Date:  1984-06-23       Impact factor: 79.321

5.  Transient hypoparathyroidism induced by synthetic human parathyroid hormone-(1-34) treatment.

Authors:  M Audran; M F Basle; A Defontaine; P Jallet; M T Bidet; A Ermias; G Tanguy; A Pouplard; J Reeve; J Zanelli
Journal:  J Clin Endocrinol Metab       Date:  1987-05       Impact factor: 5.958

6.  Development of anti-human FSH antibody in a patient with isolated FSH deficiency.

Authors:  I Spitz; J Bell; G Arad; R Benveniste; D Rabinowitz
Journal:  J Clin Endocrinol Metab       Date:  1973-04       Impact factor: 5.958

7.  Antiidiotypic PTH antibodies as a cause of elevated immunoreactive parathyroid hormone in idiopathic hypoparathyroidism, a second case: another manifestation of autoimmune endocrine disease?

Authors:  A McElduff; M Lackmann; M Wilkinson
Journal:  Calcif Tissue Int       Date:  1992-08       Impact factor: 4.333

8.  Falsely elevated serum parathyroid hormone levels due to immunoglobulin G in a patient with idiopathic hypoparathyroidism.

Authors:  K Kasono; K Sato; T Suzuki; E Ohmura; R Demura; K Shizume; T Tsushima; H Demura
Journal:  J Clin Endocrinol Metab       Date:  1991-01       Impact factor: 5.958

9.  Insulin-I131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects.

Authors:  S A BERSON; R S YALOW; A BAUMAN; M A ROTHSCHILD; K NEWERLY
Journal:  J Clin Invest       Date:  1956-02       Impact factor: 14.808

10.  Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma.

Authors:  B Cavaco; V Leite; M A Santos; E Arranhado; L G Sobrinho
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

View more
  2 in total

Review 1.  Teriparatide administration by the Omnipod pump: preliminary experience from two cases with refractory hypoparathyroidism.

Authors:  Karine Aouchiche; Rachel Reynaud; Vincent Amodru; Thierry Brue; Thomas Cuny
Journal:  Endocrine       Date:  2022-01-04       Impact factor: 3.925

Review 2.  Macroprolactinemia: diagnostic, clinical, and pathogenic significance.

Authors:  Akira Shimatsu; Naoki Hattori
Journal:  Clin Dev Immunol       Date:  2012-12-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.